ArticleVaccine2020
Recombinant infectious bronchitis coronavirus H120 with the spike protein S1 gene of the nephropathogenic IBYZ strain remains attenuated but induces protective immunity.
Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- The Vero cell-adapted infectious bronchitis virus strain rHV80 exhibits high immunogenicity and broad tissue tropism.Poultry science · 2026Article
- Seroprevalence of Infectious Bronchitis Virus Antibodies in Vaccinated Broilers from South-Western Romania (2018-2021): An ELISA-Based Survey.Veterinary sciences · 2026Article
- Construction and Immunogenicity Evaluation of a Recombinant Infectious Bronchitis Virus H120-Based Vaccine in Broiler Chickens.Animals : an open access journal from MDPI · 2026Article
- Construction and efficacy of a recombinant QX-like infectious bronchitis virus vaccine strain.Virus genes · 2025Article
- Article
- Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.Journal of virology · 2025Article
- Rapid development of attenuated IBV vaccine candidates through a versatile backbone applicable to variants.NPJ vaccines · 2025Article
- Characterization of the emerging recombinant infectious bronchitis virus in China.Frontiers in microbiology · 2024Article
- Global Emergence of Infectious Bronchitis Virus Variants: Evolution, Immunity, and Vaccination Challenges.Transboundary and emerging diseases · 2023Review
- Genetic Analysis of the Complete S1 Gene in Japanese Infectious Bronchitis Virus Strains.Viruses · 2022Article
- Characterization of the Protective Efficacy Against QX Strain of a Recombinant Infectious Bronchitis Virus With H120 Backbone and QX Spike Gene.Frontiers in microbiology · 2022Article
- Reverse Genetics and Its Usage in the Development of Vaccine Against Poultry Diseases.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Nephropathogenic Infectious Bronchitis Virus Mediates Kidney Injury in ChickensFrontiers in cellular and infection microbiology · 2022Article
- Review
- Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus.Biomedicines · 2020Review
- Construction of an infectious bronchitis virus vaccine strain carrying chimeric S1 gene of a virulent isolate and its pathogenicity analysis.Applied microbiology and biotechnology · 2020Article
- Article
- The V617I Substitution in Avian Coronavirus IBV Spike Protein Plays a Crucial Role in Adaptation to Primary Chicken Kidney Cells.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bronchitis (IB) is a highly infectious viral disease responsible for major economic losses in the poultry industry. A reverse genetic vaccine is a safe, rapid, and effective method of achieving IB prevention and control. In this study, we constructed the recombinant strain, rH120-S1/YZ, using a reverse genetic system, based on the backbone of the H120 vaccine strain, with the S1 gene replaced with that of the QX-like nephropathogenic strain, ck/CH/IBYZ/2011, isolated in China. The results of dwarf chicken embryos, growth kinetics, and viral titration in the embryos demonstrated that the biological characteristics of the recombinant virus remained unchanged. Like the rH120-infected group and in contrast to the rIBYZ-infected group, no mortality, clinical signs, or lesions were observed in the lungs or kidneys of young chickens inoculated with rH120-S1/YZ. The viral loads in various tissues, cloacal, and oral swabs was lower in most types of samples, indicating that the rH120-S1/YZ strain was highly safe in chicks. Compared to rH120 vaccination group, when the efficacy of this strain was evaluated against the QX-like IBV strain, better protection, with 100% survival rate and no disease symptom or gross lesion was observed in the chickens vaccinated with rH120-S1/YZ. Increased levels of IBV-specific antibodies were detected in the serum of the rH120-S1/YZ-vaccinated animals 14 days post-vaccination. Collectively, our results suggest that the recombinant strain, rH120-S1/YZ, may represent a promising vaccine candidate against QX-like IBVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.